Trial Profile
A Phase IB Study of Pembrolizumab in Combination With Pemetrexed and Oxaliplatin in Patients With Chemo-Refractory Metastatic Colorectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2022
Price :
$35
*
At a glance
- Drugs Oxaliplatin (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Cobalamin; Dexamethasone; Folic acid
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 09 Jul 2021 Status changed from recruiting to active, no longer recruiting.
- 25 Jan 2020 Trial design presented at the 2020 Gastrointestinal Cancers Symposium